Clément Bechtler graduated from LMU Munich in 2014 from his pharmacy degree. On completion of his practical year in 2015, he obtained his licence to practice pharmacy. He joined Dr. Geoffrey Well’s group at the University College London in the following year, where he worked on the design and synthesis of Nrf2-Keap1 protein-protein interaction inhibitors, using mostly virtual screening and organic synthetic methodology.
Clément Bechtler became a member of Prof. Ricklin’s group in May 2017.
His work is aimed at developing novel entities based on peptidic structures for complement system modulation on non-self surfaces to fend off excessive activation of this immune pathway and prevent its severe implications such as thomboinflammation or anaphylactoid reactions.